Moreover, studies of human METH abusers reveal evidence of neurotoxicity as indicated by long-term decreases in the neuronal marker, n-acetylaspartate (Ernst et al, 2000) , and in animals, long-term decreases in markers of dopamine (DA) and 5-HT terminals, including decreases in DA and 5HT transporters and content, VMAT2, and tyrosine and tryptophan hydroxylases. Despite these findings, it is unclear if these changes are indicative of actual neuronal damage, although recent evidence indicates that oxidative stress, hyperglutamatergic activity and microglial activation have important roles.
Emerging findings support the contention that METH produces excitotoxicity and oxidative damage. Calcium influx through ionotropic glutamate receptors and the activation of calcium-dependent proteases cause the breakdown of the structural membrane component, spectrin, in an AMPA receptor-dependent manner (Staszewski and Yamamoto, 2006) . Although, METH increases free radicals (Giovanni et al, 1995) , only recently has there been evidence of actual oxidative damage after METH. Eyerman and Yamamoto (2007) showed that decreases in VMAT2 after METH were likely due to the nitrosylation of VMAT2 as early as 1 h after METH. Furthermore, the nitrosylation and the long-term reduction in VMAT2 and DA transporter protein were attenuated by inhibition of neuronal nitric oxide synthase (nNOS). This indicates that METH causes a rapid glutamate and nNOSdependent oxidation of VMAT2 that precedes the long-term reductions in DA and 5HT content, thereby linking glutamate and oxidative damage to long-term decreases in markers of monoamine terminals.
Recent evidence shows that METH can affect protein degradation through oxidative damage. Impairment of the ubiquitin-proteasome system (UPS) can result in neurodegeneration such as that observed in Parkinson's disease. Most recently, Moszczynska and Yamamoto (2011) showed that METH causes an oxidative modification to parkin, one of the E3 ubiquitinprotein ligases, which add polyubiquitin chains to proteins destined for degradation. Parkin protein was decreased at 1 to 24 h after METH administration through the conjugation of parkin with 4-hydroxy-2-nonenal, a lipid peroxidation product. Moreover, METH also decreased the activity of the 26S proteasome. Both the oxidative conjugation of parkin protein and the decreased activity of the 26S proteasome were attenuated by pretreatment with antioxidant, vitamin E. Other evidence indicates that METH can oxidatively modify pyruvate kinase isoform M2, a mediator of cellular energetics and proliferation of neural progenitor cells (Venkatesan et al, 2011) , thereby producing decrements in cell metabolism and turnover.
Recently, our preliminary data indicate that a-synuclein levels increased by 200% in the striatum and hippocampus of the rat after METH. a-synuclein is a presynaptic protein that is overexpressed in some neurodegenerative conditions. Its accumulation and the eventual degeneration of the dopaminergic neuron have been associated with parkin, although a-synuclein is not traditionally considered a substrate of parkin and E3 ligase activity. This suggests that there could be a different E3 protein ligase that is oxidatively modified by METH. Further studies are warranted that examine how METH can affect the UPS and its subsequent effects on protein accumulation and degradation. 
Placental Source for 5-HT that Tunes Fetal Brain Development
Deciphering the influences of fetal programming on adult mental disorders causality depends on the identification of specific molecular pathways involved in their etiology. New insights will provide the means for reducing developmentally based disorder risk, and new therapeutic targets for treatments in adulthood. For example, our recent discovery of maternal-placental-fetal interactions that may influence brain development leads to new hypotheses regarding the mechanisms by which fetal programming of adult mental disorders may occur. A tryptophan (the precursor of serotoninF5-HT) metabolic pathway in the placenta (Bonnin et al, 2011) reflects the potential importance of extra-embryonically derived 5-HT in modulating developmental processes such as brain circuit wiring, thus affecting long-term brain function. This concept is consistent with classic genetic (5-HT1A knockout) and pharmacological (SSRI exposure) studies showing that disruption of 5-HT signaling transiently, during a restricted period of pre-or postnatal development, results in long-term behavioral abnormalities, such as increased anxiety in adulthood (Ansorge et al, 2008; Oberlander et al, 2009 ). Because many 5-HT receptors are expressed early and in complex temporal and spatial patterns during brain development (Bonnin et al, 2006) , the full extent of the mechanisms through which disruption of 5-HT signaling leads to adult phenotypes is not yet understood. One possible route through which it could occur is the disruption of the modulatory activity of 5-HT signaling on fetal forebrain wiring. This was demonstrated in vitro via the modulation of netrin-1 axon guidance activity by 5-HT, and in vivo by simultaneous, targeted disruption of two 5-HT receptors (5-HT1B/1D) (Bonnin et al, 2007) . Altered 5-HT signaling in the forebrain could preferentially influence wiring in this brain region in utero (Bonnin et al, 2007; Bonnin et al, 2011) , ultimately leading to longterm dysfunction of circuits underlying mood and emotion. Control of 5-HT signaling, through the number and/or type of 5-HT receptors activated, may thus be critical for normal brain development.
During pregnancy, altered availability of 5-HT itself also may lead to abnormal signaling in the fetal brain. The newly discovered placentaderived 5-HT accumulates in the fetal forebrain (but not the hindbrain; (Bonnin et al, 2011) ). The period during which placental 5-HT reaches the forebrain in the mouse corresponds to the first and early second trimesters in the human, prenatal periods of neuronal migration, and initial circuit formation that are associated with greater risk for mental illnesses due to maternal perturbations. Thus, like other placentaderived molecules (eg, growth factors), placental 5-HT output could be affected by both genetic (the embryo and placenta are genetically identical) and environmental disturbances that are known to increase risk for mental illnesses. In fact, altered tryptophan metabolism during pregnancy in mice has long-term functional consequences in the offspring, and has been implicated in increasing the risk for schizophrenia, bipolar disorder, and autism in humans (Miller et al, 2009) . Although long-term follow-up studies are needed, prenatal exposure to SSRI antidepressants induces an array of disturbances in childhood. It is hypothesized that maternally ingested SSRIs cross the placental barrier and directly impact fetal brain development. However, as the serotonin transporter (SERT; Slc6a4) is also highly expressed in the placenta, SSRIs may impact placental function and have indirect effects on fetal development. The SSRIs impact on placental physiology at different stages of gestation is currently under investigation, using the newly developed ex vivo dual perfusion system for the mouse placenta (Bonnin et al, 2011) .
These newest discoveries should stimulate further animal model and human research efforts to examine gene-environment influences during pregnancy that will address the developmental etiology of adult-onset mental disorders.
Mainstreaming Mice
Autism is a neurodevelopmental disorder for which diagnosis is based on three domains of behavioral symptoms: (1) abnormal social interactions, (2) impaired communication, and (3) repetitive behaviors. Currently, the only treatments that effectively improve these core symptoms are behavioral interventions implemented at early ages (Vismara and Rogers, 2010) . Although pharmacological treatments are available for associated symptoms, including self-injury, tantrums, aggression, and seizures, considerable research is needed to discover pharmacological targets for the diagnostic domains.
Mouse models of autism spectrum disorders provide translational research tools for understanding the causes of autism spectrum disorders and for developing treatments (Ehninger et al, 2008; Silverman et al, 2010) . We are interested in the mechanisms that underlie improvements in autism-relevant behavioral phenotypes in genetic mouse models. Given the effectiveness of early behavioral therapies for reducing symptoms in autism, we reasoned that behavioral interventions might similarly rescue social and/or repetitive abnormalities in mouse models. To test this hypothesis, we used an inbred strain of mice, BTBR T + tf/J (BTBR), which displays low sociability on multiple social tasks, reduced ultrasonic vocalizations
